StockData
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc. (NTLA) stock

NTLANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/307% above fair value
$9.77−0.01 (-0.10%)

Close on Nov 18, 2026Market cap $1.37BP/E –Yield –

Intellia Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Intellia Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$423.48M. For fiscal 2025 it was -$440.99M. The highest annual figure on record is -$13.41M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$440.99M–
FY2024Dec 31, 2024-$534.26M–
FY2023Dec 31, 2023-$515.29M–
FY2022Dec 31, 2022-$458.16M–
FY2021Dec 31, 2021-$267.85M–
FY2020Dec 31, 2020-$136.58M–
FY2019Dec 31, 2019-$106.37M–
FY2018Dec 31, 2018-$90.87M–
FY2017Dec 31, 2017-$69.56M–
FY2016Dec 31, 2016-$32.16M–
FY2015Dec 31, 2015-$13.41M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$112.76M–
Q1 FY2026Mar 31, 2026-$100.53M–
Q4 FY2025Dec 31, 2025-$98.71M–
Q3 FY2025Sep 30, 2025-$111.48M–
Q2 FY2025Jun 30, 2025-$110.00M–
Q1 FY2025Mar 31, 2025-$120.81M–
Q4 FY2024Dec 31, 2024-$136.45M–
Q3 FY2024Sep 30, 2024-$144.77M–
Q2 FY2024Jun 30, 2024-$139.04M–
Q1 FY2024Mar 31, 2024-$114.00M–
Q4 FY2023Dec 31, 2023-$139.89M–
Q3 FY2023Sep 30, 2023-$131.11M–
Q2 FY2023Jun 30, 2023-$132.33M–
Q1 FY2023Mar 31, 2023-$111.96M–
Q4 FY2022Dec 31, 2022-$110.09M–
Q3 FY2022Sep 30, 2022-$105.53M–
Q2 FY2022Jun 30, 2022-$98.30M–
Q1 FY2022Mar 31, 2022-$144.25M–
Q4 FY2021Dec 31, 2021-$80.42M–
Q3 FY2021Sep 30, 2021-$71.99M–
Q2 FY2021Jun 30, 2021-$69.02M–
Q1 FY2021Mar 31, 2021-$46.43M–
Q4 FY2020Dec 31, 2020-$42.40M–
Q3 FY2020Sep 30, 2020-$28.10M–
Q2 FY2020Jun 30, 2020-$33.03M–
Q1 FY2020Mar 31, 2020-$33.05M–
Q4 FY2019Dec 31, 2019-$29.77M–
Q3 FY2019Sep 30, 2019-$25.33M–
Q2 FY2019Jun 30, 2019-$27.46M–
Q1 FY2019Mar 31, 2019-$23.81M–
Q4 FY2018Dec 31, 2018-$20.75M–
Q3 FY2018Sep 30, 2018-$24.10M–
Q2 FY2018Jun 30, 2018-$23.60M–
Q1 FY2018Mar 31, 2018-$22.43M–
Q4 FY2017Dec 31, 2017-$24.72M–
Q3 FY2017Sep 30, 2017-$15.88M–
Q2 FY2017Jun 30, 2017-$16.02M–
Q1 FY2017Mar 31, 2017-$12.95M–
Q4 FY2016Dec 31, 2016-$10.82M–
Q3 FY2016Sep 30, 2016-$7.70M–

More Intellia Therapeutics figures

See a number that looks wrong?